Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
基本信息
- 批准号:10306036
- 负责人:
- 金额:$ 31.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-15 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAcuteAdmission activityAdultAfrican AmericanAncillary StudyAreaAsiansBiological MarkersCarotid StenosisChildhood strokeClinicalClinical ResearchClinical TrialsCognitionCountyDataDevelopmentDiseaseEnrollmentFailureFellowshipFundingGoalsHeart AtriumHispanicsHospitalsHumanInfrastructureInstitutionK-Series Research Career ProgramsLeadershipManuscriptsMentorsMinority GroupsNeurologistNeurosciencesNew JerseyNew YorkOutcome StudyPatientsPhasePhase II Clinical TrialsPhase III Clinical TrialsPopulationPopulations at RiskPositioning AttributeProductivityRandomized Controlled TrialsRecoveryRehabilitation CentersRehabilitation therapyResourcesRoleScienceSideSiteStandardizationStrokeStroke preventionTestingTrainingTraining and EducationUnited States National Institutes of HealthWorkacute strokecareercerebral hemodynamicsclinical trial enrollmentcryptogenic strokedemographicsdisabilityexperienceimprovedinnovationmedical schoolsmortalitymulti-ethnicneurosurgerynext generationpatient subsetsprofessorprogramsscreeningstroke clinical trialsstroke outcomestroke recoverystroke therapystroke trialssuccesstreatment centerunderserved minorityworking group
项目摘要
The Stroke Trials Network of Columbia and Cornell (STNCC) has a primary goal of
maximizing stroke clinical trial enrollment for New York. Columbia and Cornell, situated on the
west and east side of Manhattan, respectively, will form the two hubs, supported by an Acute
Treatment Sub-network of 3 hospitals in Brooklyn and New Jersey, a Recovery Sub-network
comprising 2 affiliated academic Rehabilitation Centers in Westchester County and New Jersey,
and 4 Academic Medical Centers in Brooklyn and in Western New York. Our hubs and satellites
treated just over 6,700 strokes in 2016. More importantly, our RCC has an extensive leadership
record in stroke clinical trials, and have the distinction of being the leading enroller in Stroke
clinical trials over the first 5 years of StrokeNet; Our total enrollment as of August, 2017 was 375
subjects. Historically, over the last 10 years, Columbia and Cornell have been involved in 44
human stroke studies, including 29 stroke clinical trials, 10 stroke biomarker studies, and 5
stroke outcomes studies. The demographics in our network overall are very favorable for
enrolling underserved minority populations: Columbia has 40% Hispanic and 25% African
American; Cornell 15% Asian, and St. Joseph's 24% African American, 30% Hispanic, 12%
other. Part of our success is due to the highly organized and interactive infrastructure. We hold
monthly videoconferences attended by PIs and coordinators from all RCC hubs and satellite
sites, and standardized daily stroke admission screening across the RCC. These data as well
as trial enrollments are reviewed at the monthly videoconference calls. The STNCC has also
provided leadership at the national level in the first 5 years of StrokeNet. Contact PI Randolph
Marshall served on the NCC Executive Committee for the first 3 years, as Co-Chair of the
Education and Training Core for all 5 years, and on the Recovery and Rehabilitation Working
Group over the last year. He has been invited to continue the latter two roles in the upcoming
renewal period. Co-I Ronald Lazar, now at UAB, served on the Recovery and Rehab WG for
three years, and Co-PI E Sander Connolly has served on the Neurosurgery advisory group. In
terms of innovation and clinical trial development, our RCC has the distinction of submitting
and obtaining funding for two of the new StrokeNet studies. STNCC Co-Is Mitchell Elkind and
Hooman Kamel are Co-PI's on the ARCADIA trial, a multi-center Phase 3 RCT to determine
whether apixaban is superior to standard therapy for patients with cryptogenic stroke and “atrial
cardiopathy.” Randolph Marshall, Sander Connolly, and Ronald Lazar are Co-PI's on the
CREST-H study, an ancillary study to the CREST-2 trial, testing the hypothesis that
revascularization can improve cognition in as subset of patients with high grade asymptomatic
carotid stenosis who have cerebral hemodynamic failure. Finally, our StrokeNet trainee program
has been highly successful, with 5 trainees producing 22 abstracts and 21 manuscripts within 1
year of Fellowship, and 4 so far have Assistant Professor positions at major academic
institutions (all StrokeNet sites). Two are applying for K-awards.
哥伦比亚和康奈尔的中风试验网络(STNCC)的主要目标是
最大限度地增加纽约中风临床试验的参与人数。哥伦比亚和康奈尔大学,位于
曼哈顿的东西两侧将分别形成两个中心,由一个Acute
布鲁克林和新泽西3家医院的治疗子网络,恢复子网络
包括韦斯特切斯特县和新泽西的2个附属学术康复中心,
以及布鲁克林和纽约西部的4个学术医疗中心。我们的枢纽和卫星
2016年治疗了6,700多例中风更重要的是,我们的RCC拥有广泛的领导力,
在中风临床试验中的记录,并有区别的是领先的登记中风
StrokeNet前5年的临床试验;截至2017年8月,我们的总入组人数为375人
科目从历史上看,在过去的10年里,哥伦比亚和康奈尔大学已经参与了44个
人类卒中研究,包括29项卒中临床试验、10项卒中生物标志物研究和5项
卒中结局研究。我们网络中的人口统计数据总体上非常有利于
招收服务不足的少数民族人口:哥伦比亚有40%的西班牙裔和25%的非洲裔
美国人;康奈尔15%亚洲人,圣约瑟夫24%非洲裔美国人,30%西班牙裔,12%
其他.我们的成功部分归功于高度组织化和互动的基础设施。我们持有
所有区域协调中心和卫星中心的主要研究员和协调员参加每月视频会议
中心,并在RCC中进行标准化的每日卒中入院筛查。这些数据也
因为每月的视频电话会议审查试验入组情况。STNCC还
在StrokeNet的头5年里,在国家一级发挥了领导作用。联系PI兰多夫
马歇尔担任NCC执行委员会的前3年,作为联合主席,
所有5年的教育和培训核心,以及恢复和康复工作
去年一年里。他被邀请在即将到来的
更新期。Co-I罗纳德拉扎尔,现在在UAB,在恢复和康复工作组任职,
三年来,和共同PI E桑德康诺利已担任神经外科顾问组。在
在创新和临床试验开发方面,我们的RCC具有提交
并为两项新的中风网络研究获得资金。STNCC Co-Is Mitchell Elkind和
Hooman Kamel是ARCADIA试验的共同PI,这是一项多中心III期RCT,旨在确定
阿哌沙班是否上级优于标准治疗隐源性卒中和“心房颤动”患者
心脏病”兰多夫马歇尔,桑德康诺利,和罗纳德拉扎尔是共同PI的
CREST-H研究,CREST-2试验的辅助研究,检验以下假设:
血运重建可以改善高级别无症状患者的认知功能,
脑血流动力学衰竭的颈动脉狭窄患者。最后,我们的StrokeNet培训生计划
已取得很大成功,5名受训人员在1年内编写了22份摘要和21份手稿,
一年的奖学金,4迄今已助理教授职位,在主要学术
机构(所有StrokeNet网站)。两人申请K奖。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD SANDER CONNOLLY其他文献
EDWARD SANDER CONNOLLY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD SANDER CONNOLLY', 18)}}的其他基金
Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
- 批准号:
10767024 - 财政年份:2023
- 资助金额:
$ 31.68万 - 项目类别:
Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
- 批准号:
9571820 - 财政年份:2018
- 资助金额:
$ 31.68万 - 项目类别:
Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
- 批准号:
9983213 - 财政年份:2018
- 资助金额:
$ 31.68万 - 项目类别:
Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
- 批准号:
10468292 - 财政年份:2018
- 资助金额:
$ 31.68万 - 项目类别:
Stroke Trials Network of Columbia and Cornell
哥伦比亚大学和康奈尔大学中风试验网络
- 批准号:
9764512 - 财政年份:2018
- 资助金额:
$ 31.68万 - 项目类别:
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
无症状颈动脉狭窄试验的颈动脉血运重建和医疗管理 - 血流动力学 (CREST-H)
- 批准号:
9311842 - 财政年份:2017
- 资助金额:
$ 31.68万 - 项目类别:
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
无症状颈动脉狭窄试验的颈动脉血运重建和医疗管理 - 血流动力学 (CREST-H)
- 批准号:
9923010 - 财政年份:2017
- 资助金额:
$ 31.68万 - 项目类别:
Statin Neuroprotection & Cognitive Dysfunction after Carotid Endarterectomy: Safety, Feasibility, & Outcomes.
他汀类药物神经保护
- 批准号:
9176594 - 财政年份:2016
- 资助金额:
$ 31.68万 - 项目类别:
Topical Vancomycin for Craniotomy Wound Prophylaxis
外用万古霉素用于预防开颅手术伤口
- 批准号:
8868935 - 财政年份:2014
- 资助金额:
$ 31.68万 - 项目类别:
Topical Vancomycin for Craniotomy Wound Prophylaxis
外用万古霉素用于预防开颅手术伤口
- 批准号:
8674351 - 财政年份:2014
- 资助金额:
$ 31.68万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 31.68万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 31.68万 - 项目类别:
Standard Grant